BACKGROUND AND OBJECTIVE: Low nucleotide excision repair (NER) capacity has been associated with increased risk of lung cancer. Excision repair cross-complementing group 1 (ERCC1) is one of the NER core enzymes, and polymorphisms in ERCC1 may lead to altered repair function of the enzyme and therefore confer predisposition to cancer. The goal of this study was to test the hypothesis that common variants in ERCC1 were associated with lung cancer risk. METHODS: The genotyping analyses for 7 selected single nucleotide polymorphisms in ERCC1 using the TaqMan assay was conducted in a case-control study of 1010 patients with incident lung cancer and 1011 cancer-free controls in a Chinese population. RESULTS: We found that the variant genotypes of the rs3212948 C allele were associated with significantly decreased risk of lung cancer [adjusted odds ratio (OR)=0.73 (95% CI=0.60-0.88) for CG; 0.96 (95% CI=0.65-1.41) for CC and 0.76 (95% CI=0.63-0.91) for CG/CC, compared with the GG genotype]. Similarly, a significant protective effect was also evident for the variant genotypes of rs1007616 C/T [adjusted OR=0.72 (95% CI=0.59-0.89) for CT; 0.90 (95% CI=0.61-1.35) for TT and 0.75 (95% CI=0.62-0.91) for CT/TT, compared with the CC genotype]. Stratified analysis revealed that the protective effects of these 2 single nucleotide polymorphisms were both more evident among young patients and patients without family history of cancer. Consistently, when assessing each unique haplotype compared with the most common haplotype 'TAGCACG', lung cancer risk was significantly decreased among patients who carried the haplotype 'TCCCATT' with the variant rs3212948C and rs1007616T alleles (P value=0.0340, P-sim=0.0325, adjusted OR=0.78; 95% CI=0.63-0.97). CONCLUSION: These findings indicate that ERCC1 polymorphisms may contribute to the etiology of lung cancer. Further functional studies were warranted to elucidate the mechanism of the associations.
BACKGROUND AND OBJECTIVE: Low nucleotide excision repair (NER) capacity has been associated with increased risk of lung cancer. Excision repair cross-complementing group 1 (ERCC1) is one of the NER core enzymes, and polymorphisms in ERCC1 may lead to altered repair function of the enzyme and therefore confer predisposition to cancer. The goal of this study was to test the hypothesis that common variants in ERCC1 were associated with lung cancer risk. METHODS: The genotyping analyses for 7 selected single nucleotide polymorphisms in ERCC1 using the TaqMan assay was conducted in a case-control study of 1010 patients with incident lung cancer and 1011 cancer-free controls in a Chinese population. RESULTS: We found that the variant genotypes of the rs3212948 C allele were associated with significantly decreased risk of lung cancer [adjusted odds ratio (OR)=0.73 (95% CI=0.60-0.88) for CG; 0.96 (95% CI=0.65-1.41) for CC and 0.76 (95% CI=0.63-0.91) for CG/CC, compared with the GG genotype]. Similarly, a significant protective effect was also evident for the variant genotypes of rs1007616 C/T [adjusted OR=0.72 (95% CI=0.59-0.89) for CT; 0.90 (95% CI=0.61-1.35) for TT and 0.75 (95% CI=0.62-0.91) for CT/TT, compared with the CC genotype]. Stratified analysis revealed that the protective effects of these 2 single nucleotide polymorphisms were both more evident among young patients and patients without family history of cancer. Consistently, when assessing each unique haplotype compared with the most common haplotype 'TAGCACG', lung cancer risk was significantly decreased among patients who carried the haplotype 'TCCCATT' with the variant rs3212948C and rs1007616T alleles (P value=0.0340, P-sim=0.0325, adjusted OR=0.78; 95% CI=0.63-0.97). CONCLUSION: These findings indicate that ERCC1 polymorphisms may contribute to the etiology of lung cancer. Further functional studies were warranted to elucidate the mechanism of the associations.
Authors: Ming Yin; Jingrong Yan; Alexandra Voutsina; Carmelo Tibaldi; David C Christiani; Rebecca S Heist; Rafael Rosell; Richard Booton; Qingyi Wei Journal: Lung Cancer Date: 2010-11-13 Impact factor: 5.705
Authors: Claudia M Monroy; Andrea C Cortes; Mirtha Lopez; Elizabeth Rourke; Carol J Etzel; Anas Younes; Sara S Strom; Randa El-Zein Journal: Mol Carcinog Date: 2011-03-03 Impact factor: 4.784
Authors: Nathan R Jones; Thomas E Spratt; Arthur S Berg; Joshua E Muscat; Philip Lazarus; Carla J Gallagher Journal: Cancer Epidemiol Date: 2010-09-21 Impact factor: 2.984
Authors: Caglayan Geredeli; Mehmet Artac; Selman Yildirim; Ali Inal; Isa Dede; Tunc Guler; Melih Cem Boruban; Lokman Koral; Mustafa Karaagac; Ayse Gul Zamani; Tamer Altinok; Olgun Aribas; Hakan Bozcuk; Ahmet Demirkazik Journal: Tumour Biol Date: 2015-01-18